BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Phase 2

Completed

Conditions: Hodgkin Disease

Interventions: Drug: Nivolumab
Drug: Doxorubicin
Drug: Vinblastine
Drug: Dacarbazine

First Posted Date: 2014-07-04

Last Posted Date: 2023-11-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 294

Registration Number: NCT02181738

Locations: 🇺🇸
Local Institution - 0025, Boston, Massachusetts, United States
🇮🇹
Local Institution - 0019, Bologna, Italy
🇬🇧
Local Institution - 0026, Oxford, Oxfordshire, United Kingdom

and more 35 locations

Study of Drug Combination on Pharmacokinetics in Healthy Volunteers

Phase 1

Completed

Conditions: Hepatitis C Infection

Interventions: Drug: Sertraline
Drug: Escitalopram
Drug: DCV 3DAA FDC
Drug: BMS-791325

First Posted Date: 2014-06-26

Last Posted Date: 2015-02-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 41

Registration Number: NCT02175602

Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: DCV/ASV/BMS-791325
Drug: Sofosbuvir
Drug: Ribavirin
Drug: Peginterferon α-2a

First Posted Date: 2014-06-26

Last Posted Date: 2020-08-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 35

Registration Number: NCT02175966

Locations: 🇺🇸
Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸
Indiana University Health - University Hospital, Indianapolis, Indiana, United States
🇺🇸
Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States

and more 4 locations

A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1

Phase 3

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: DCV/ASV/BMS-791325

First Posted Date: 2014-06-23

Last Posted Date: 2020-10-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 199

Registration Number: NCT02170727

Locations: 🇨🇳
Local Institution, Taoyuan, Taiwan

Post-marketing Study Assessing the Long-Term Safety of Abatacept

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept

First Posted Date: 2014-06-23

Last Posted Date: 2017-04-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 100000

Registration Number: NCT02169544

Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects

Phase 1

Completed

Conditions: HIV/AIDS

Interventions: Drug: Moxifloxacin
Drug: Placebo
Drug: Efavirenz

First Posted Date: 2014-06-17

Last Posted Date: 2015-09-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 58

Registration Number: NCT02164812

Locations: 🇺🇸
Parexel International - Baltimore Epcu, Baltimore, Maryland, United States

A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C

Conditions: Chronic Hepatitis C

First Posted Date: 2014-06-12

Last Posted Date: 2016-01-29

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT02161939

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇺🇸
Piedmont Transplant, Atlanta, Georgia, United States

and more 17 locations

Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: Daclatasvir
Drug: Darunavir
Drug: Lopinavir/Ritonavir
Drug: Ritonavir

First Posted Date: 2014-06-09

Last Posted Date: 2015-11-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 49

Registration Number: NCT02159352

Locations: 🇺🇸
Healthcare Discoveries, Llc D/B/A Icon Development Solutions, San Antonio, Texas, United States

Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2014-06-09

Last Posted Date: 2019-07-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 84

Registration Number: NCT02159365

Locations: 🇺🇸
Baptist Health Medical Group Oncology, Miami, Florida, United States
🇺🇸
Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States
🇺🇸
Comprehensive Blood And Cancer Center, Bakersfield, California, United States

and more 26 locations

A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure

Phase 2

Completed

Conditions: Heart Failure
Decompensated Heart Failure
Acute Heart Failure

Interventions: Drug: Placebo
Drug: CXL-1427

First Posted Date: 2014-06-06

Last Posted Date: 2019-07-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 70

Registration Number: NCT02157506

Locations: 🇷🇺
Cardioxyl Study Site, Tomsk, Russian Federation
🇵🇱
Cardioxyl Study SIte, Warsaw, Poland

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy